IP Library › Granted Patent US 10,822,391
Granted Patent B2
US 10,822,391 · App. 12/731,772 · Granted Nov 3, 2020

Fusion proteins and methods for inhibiting IL-17 pathways

Inventors: Abraham Scaria (Framingham, MA); Gary White (Marlborough, MA)
Assignee: GENZYME CORPORATION
C07K14/7155A61K38/00C07K2319/30C12N2750/14143
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,822,391
App. No.
12/731,772
Granted
Nov 3, 2020
Kind
B2
Abstract

Fusion proteins including an IL-17 receptor with a multimerization domain, or an IL-23 receptor and a multimerization domain, and recombinant viral vectors encoding such fusions, are described. The fusion proteins and vectors encoding such fusions, alone or in combination, can be used in methods for modulating the IL-17 and IL-23 signaling pathways and for treating or preventing diseases mediated by interleukin-17 and interleukin-23, such as immune-related and inflammatory diseases.

Claims (1)

1. An IL-17 receptor fusion protein comprising the amino acid sequence of SEQ ID NO: 8.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2011
From: SCARIA, ABRAHAM; WHITE, GARY
To: GENZYME CORPORATION
Reel/Frame 026273/0523 →
Continuity (3)
Continuation PCTUS2008011086 · Sep 25, 2008
Provisional Application 60974892 · Sep 25, 2007
Related Publication 20110052585A1 · Mar 3, 2011